Angeion: Life After St. Jude
Executive Summary
Angeion thought it was going to get to the implantable defibrillator market with St. Jude as a marketing partner. But St. Jude's acquisition of Ventritex changed all that. Now, Angeion is going it alone, with worldwide royalty-free licenses from St. Jude on a wide range of patents. But can Angeion use that base and what company officials believe is superior technology to succeed in a market increasingly dominated by giants?
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.